US Bancorp
KLRS

US Bancorp’s Kalaris Therapeutics KLRS Stock Holding History

US Bancorp’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-19
Closed -$950 – 4174
2023
Q3 		$950 Buy
+19
New +$1.29K ﹤0.01% 3777
2022
Q1 		– Sell
-4
Closed -$1K – 4230
2021
Q4 		$1K Sell
4
-7
-64% -$3.25K ﹤0.01% 4051
2021
Q3 		$6K Buy
11
+4
+57% +$1.85K ﹤0.01% 3612
2021
Q2 		$3K Buy
+7
New +$3.61K ﹤0.01% 3773

Other funds holding KLRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

US Bancorp's KLRS Position: Q4 2023 in Review

US Bancorp sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 19 shares — an estimated $950 sold.

US Bancorp first reported a position in KLRS in Q2 2021 and held it in 4 quarters. The position peaked at $6K in Q3 2021. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • US Bancorp reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • US Bancorp sold 19 Kalaris Therapeutics shares in Q4 2023, an estimated $950.
  • US Bancorp first reported a position in Kalaris Therapeutics in Q2 2021 and held it in 4 quarters.
  • US Bancorp's Kalaris Therapeutics position peaked at $6K in Q3 2021.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on US Bancorp's 13F filing for Q4 2023, filed 9 Feb 2024.